Non-muscle Invasive Bladder Cancer (NMIBC) Market is Projected to Grow Significantly by 2036 Owing to the Launch of Novel Intravesical Therapies and Immunotherapies | DelveInsight

The market dynamics for Non-muscle Invasive Bladder Cancer (NMIBC) are witnessing steady growth driven by the rising incidence and diagnosis rates of bladder cancer, increasing demand for effective bladder-preserving therapies, and growing adoption of advanced intravesical immunotherapies and gene therapies. Additionally, the launch of emerging therapies such as TAR-200 (Johnson & Johnson), UGN-102 (UroGen Pharma), Nadofaragene Firadenovec (Ferring Pharmaceuticals), and others will further fuel the market.

DelveInsight, a leading market research firm, announces the release of its latest report, "DelveInsight's Non-muscle Invasive Bladder Cancer Market Insights, Epidemiology, and Market Forecast 2036." This comprehensive report provides an in-depth understanding of Non-muscle Invasive Bladder Cancer (NMIBC), including historical and forecasted epidemiology, market trends, and treatment scenarios across the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan.

Key Takeaways from the Non-muscle Invasive Bladder Cancer (NMIBC) Market
• The market size for Non-muscle Invasive Bladder Cancer (NMIBC) in the leading markets is expected to grow significantly by 2036.
• The United States accounted for the highest Non-muscle Invasive Bladder Cancer (NMIBC) treatment market size in 7MM in 2025, in comparison to the other major markets, i.e., EU4 countries, the United Kingdom, and Japan.
• DelveInsight's analysis indicates that NMIBC accounts for nearly 70-75% of all newly diagnosed bladder cancer cases, highlighting the substantial disease burden globally.
• According to estimates, bladder cancer remains one of the most commonly diagnosed urological cancers, with a significant proportion of patients presenting with NMIBC at diagnosis.
• Increasing recurrence and progression rates in high-risk NMIBC continue to create a substantial unmet need for effective long-term treatment approaches.
• Leading NMIBC companies, such as Johnson & Johnson, UroGen Pharma, Ferring Pharmaceuticals, CG Oncology, ImmunityBio, and others, are developing new NMIBC treatment drugs that can be available in the NMIBC market in the coming years.
• The promising NMIBC therapies in clinical trials include TAR-200, UGN-102, Nadofaragene Firadenovec, Cretostimogene Grenadenorepvec, N-803, and others.

Keen to know more about the market? Request our sample page at
https://www.delveinsight.com/sample-request/non-muscle-invasive-bladder-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kspr

Key Factors Driving the Non-muscle Invasive Bladder Cancer (NMIBC) Market
• Rising Disease Prevalence and Diagnosis Rates: Increasing prevalence of bladder cancer, improved diagnostic procedures such as cystoscopy and urine cytology, and growing awareness regarding early-stage bladder cancer are helping identify more patients with NMIBC. Earlier diagnosis and improved surveillance practices are contributing to treatment demand.
• Increasing Demand for Effective Intravesical and Bladder-preserving Therapies: The treatment of NMIBC primarily involves transurethral resection of bladder tumor (TURBT), Bacillus Calmette-Guérin (BCG) immunotherapy, intravesical chemotherapy, and bladder-preserving treatment approaches. The limitations associated with recurrence and BCG-unresponsive disease are accelerating demand for novel therapies.
• Growing Preference for Advanced Immunotherapies and Gene Therapies: Emerging intravesical drug delivery systems, oncolytic immunotherapies, and adenoviral gene therapies are increasingly gaining traction. These advanced therapeutic approaches are designed to improve disease-free survival, reduce recurrence rates, and minimize the need for radical cystectomy.

Non-muscle Invasive Bladder Cancer (NMIBC) Competitive Landscape
• Several NMIBC drugs in development include TAR-200 (Johnson & Johnson), UGN-102 (UroGen Pharma), Nadofaragene Firadenovec (Ferring Pharmaceuticals), Cretostimogene Grenadenorepvec (CG Oncology), and N-803 (ImmunityBio).
• These candidates target diverse mechanisms such as sustained intravesical drug delivery (TAR-200), reverse thermal hydrogel-based chemotherapy delivery (UGN-102), adenoviral vector-based gene therapy (Nadofaragene Firadenovec), oncolytic immunotherapy (Cretostimogene Grenadenorepvec), and IL-15 superagonist immunotherapy (N-803), aiming to improve disease control in NMIBC patients with better efficacy and bladder preservation outcomes than current treatments.

Discover more about therapies set to grab major Non-muscle Invasive Bladder Cancer (NMIBC) market share @ https://www.delveinsight.com/sample-request/non-muscle-invasive-bladder-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kspr

Recent Developments in the Non-muscle Invasive Bladder Cancer (NMIBC) Market
• In recent years, Johnson & Johnson continued evaluating TAR-200 across multiple clinical studies in patients with BCG-unresponsive NMIBC.
• UroGen Pharma reported ongoing development activities for UGN-102 in low-grade intermediate-risk NMIBC patients.
• Ferring Pharmaceuticals strengthened its NMIBC treatment portfolio with continued commercialization and clinical evaluation of Nadofaragene Firadenovec.
• CG Oncology and ImmunityBio are actively advancing late-stage clinical trials evaluating novel immunotherapeutic approaches for high-risk NMIBC patients.

What is Non-muscle Invasive Bladder Cancer (NMIBC)?
Non-muscle Invasive Bladder Cancer (NMIBC) is a type of bladder cancer in which the tumor remains confined to the inner lining of the bladder and has not invaded the muscular wall. NMIBC represents the majority of newly diagnosed bladder cancer cases and is characterized by high recurrence rates despite available treatments. Common symptoms include hematuria, painful urination, urinary urgency, and frequent urination. Early diagnosis and effective intravesical therapy are critical for reducing recurrence and preventing disease progression.

Non-muscle Invasive Bladder Cancer (NMIBC) Epidemiology Segmentation
The Non-muscle Invasive Bladder Cancer (NMIBC) epidemiology section provides insights into the historical and current Non-muscle Invasive Bladder Cancer (NMIBC) patient pool and forecasted trends for the leading markets. The NMIBC market report proffers epidemiological analysis for the study period 2022-2036 in the leading markets, segmented into:
• Total Diagnosed Prevalent Cases of Non-muscle Invasive Bladder Cancer (NMIBC)
• Stage-specific Diagnosed Prevalent Cases of NMIBC
• Risk-specific Diagnosed Prevalent Cases of NMIBC
• Age-specific Diagnosed Prevalent Cases of NMIBC

Scope of the Non-muscle Invasive Bladder Cancer (NMIBC) Market Report
• Therapeutic Assessment: NMIBC current marketed and emerging therapies
• NMIBC Market Dynamics: Key Market Forecast Assumptions of Emerging NMIBC Drugs and Market Outlook
• Key Companies: Johnson & Johnson, UroGen Pharma, Ferring Pharmaceuticals, CG Oncology, ImmunityBio, and others
• Key Therapies: TAR-200, UGN-102, Nadofaragene Firadenovec, Cretostimogene Grenadenorepvec, N-803, and others
• Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
• Unmet Needs, KOL's views, Analyst's views, NMIBC Market Access and Reimbursement

To know more about NMIBC companies working in the treatment market, visit @ https://www.delveinsight.com/sample-request/non-muscle-invasive-bladder-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kspr

Table of Contents
• Non-muscle Invasive Bladder Cancer (NMIBC) Market Report Introduction
• Executive Summary for NMIBC
• SWOT Analysis of NMIBC
• NMIBC Patient Share (%) Overview at a Glance
• NMIBC Market Overview at a Glance
• NMIBC Background and Overview
• NMIBC Epidemiology and Patient Population
• Country-Specific Patient Population of NMIBC
• NMIBC Current Treatment and Medical Practices
• NMIBC Unmet Needs
• NMIBC Emerging Therapies
• NMIBC Market Outlook
• Country-Wise NMIBC Market Analysis (2022-2036)
• NMIBC Market Access and Reimbursement of Therapies
• NMIBC Market Drivers
• NMIBC Market Barriers
• NMIBC Appendix
• NMIBC Report Methodology
• DelveInsight Capabilities
• Disclaimer
• About DelveInsight

Company Name: DelveInsight Business Research LLP
Contact Person: Kirti Sharma
Email: info@delveinsight.com
Phone: +14699457679
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

This release was published on openPR.